 TORONTO and HOUSTON, Dec. 30, 2020 GLOBE NEWSWIRE -- Medicenna Therapeutics Corp. Medicenna or the Company NASDAQ: MDNA, TSX: MDNA, a clinical stage immuno-oncology company, announced today that it has entered into a sales agreement with SVB Leerink acting as sales agent the Sales Agreement, pursuant to which the Company may, from time to time sell, through at-the-market offerings on the Nasdaq Capital Market the Nasdaq such number of common shares as would have an aggregate offering price of up to US25 million the ATM Offering under the ATM Prospectus Supplement as defined below. 